/MDCX
MDCX Stock - Medicus Pharma Ltd. Common Stock
Healthcare|BiotechnologyNASDAQ
$1.69+1.81%
+$0.03 (+1.81%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.86
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MDCX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.67 – $1.71
TARGET (TP)$1.94
STOP LOSS$1.55
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.98
52W High$8.94
52W Low$1.59
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-11,180,902 | $-4,729,945 | $-978,416 | $-1,441,388 |
| Net Income | $-11,155,516 | $-5,314,765 | $-1,692,382 | $-2,055,263 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $-1.10 | $-1.53 | $-0.88 | $-0.26 |
Company Overview
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MDCXBeat Rate
25%
Last 8 quarters
Avg Surprise
-34.1%
EPS vs Estimate
Beats / Misses
2/6
Last 12 quarters
Latest EPS
$-0.65
Q4 2025
EPS Surprise History
Q4 23
-2.0%
$-0.31vs$-0.30
Q2 24
+16.7%
$-0.15vs$-0.18
Q3 24
-126.7%
$-0.34vs$-0.15
Q4 24
-40.6%
$-0.31vs$-0.22
Q1 25
+43.8%
$-0.18vs$-0.32
Q2 25
-82.6%
$-0.42vs$-0.23
Q3 25
-10.3%
$-0.43vs$-0.39
Q4 25
-71.1%
$-0.65vs$-0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.37 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.38 | $-0.65 | -71.1% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.39 | $-0.43 | -10.3% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-0.23 | $-0.42 | -82.6% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | $-0.32 | $-0.18 | +43.8% | ✓ BEAT |
Q4 2024 | Nov 22, 2024 | $-0.22 | $-0.31 | -40.6% | ✗ MISS |
Q3 2024 | Aug 22, 2024 | $-0.15 | $-0.34 | -126.7% | ✗ MISS |
Q2 2024 | May 30, 2024 | $-0.18 | $-0.15 | +16.7% | ✓ BEAT |
Q4 2023 | Dec 31, 2023 | $-0.30 | $-0.31 | -2.0% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | — | $-1.47 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.06 | — | — |
Latest News
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
📈 PositiveBenzinga•Dec 15, 2025, 01:16 PM
Medicus Pharma Completes 90 Patient Phase 2 SKNJCT-003 Enrollment And Targets Topline Results Before End Of Q1 2026
📈 PositiveBenzinga•Dec 15, 2025, 12:35 PM
Medicus Pharma Entered Into A Warrant Inducement Agreement For The Immediate Exercise Of 2.68M Warrants At $1.92, Issues 4.02M New Series C & D Warrants At $2.00; Gross Proceeds Are Expected To Be ~$5.1M
➖ NeutralBenzinga•Dec 5, 2025, 08:26 PM
Medicus Pharma Appoints Carolyn Bonner As CFO
➖ NeutralBenzinga•Dec 1, 2025, 01:05 PM
Medicus Pharma Appoints Carolyn Bonner As CFO, Effective Immediately
➖ NeutralBenzinga•Dec 1, 2025, 12:42 PM
Medicus Pharma Elevates President Carolyn Bonner to CFO as Co-Founder Jim Quinlan Steps Down for Health Reasons
➖ NeutralBenzinga•Dec 1, 2025, 12:37 PM
Medicus Pharma To Explore Treatment Innovations In Prostate And Skin Cancer Treatment
📈 PositiveBenzinga•Nov 24, 2025, 01:05 PM
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
📈 PositiveBenzinga•Nov 17, 2025, 01:28 PM
Medicus Pharma Seeks Fast-Track FDA Voucher for New Skin Cancer Treatment
📈 PositiveBenzinga•Nov 17, 2025, 12:35 PM
Medicus Pharma Q3 EPS $(1.12) Misses $(0.29) Estimate
📉 NegativeBenzinga•Nov 14, 2025, 10:01 PM
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 01:10 PM
Medicus Pharma Receives UK Regulatory And Ethical Approvals To Expand Phase 2 Clinical Study To Non-Invasively Treat Basal Cell Carcinoma Of The Skin
📈 PositiveBenzinga•Nov 13, 2025, 12:32 PM
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
📈 PositiveBenzinga•Oct 29, 2025, 12:46 PM
Medicus Pharma Partners With Gorlin Syndrome Alliance To Enhance Access To SKINJECT For Gorlin Syndrome Patients
📈 PositiveBenzinga•Oct 29, 2025, 11:34 AM
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
📈 PositiveBenzinga•Oct 22, 2025, 02:06 PM
Medicus Pharma Begins UAE Trial for Non-Invasive Skin Cancer Treatment
📈 PositiveBenzinga•Oct 22, 2025, 11:35 AM
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
📈 PositiveBenzinga•Oct 14, 2025, 06:05 PM
D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $27 Price Target
📈 PositiveBenzinga•Sep 29, 2025, 02:23 PM
Medicus Pharma Announces Positive Feedback From Type C Meeting FDA; Targets Q4 Completion Of SKNJCT-003 Recruitment And Q1 2026 EOP2 Meeting
📈 PositiveBenzinga•Sep 29, 2025, 11:33 AM
Medicus Pharma To Present Update On D-MNA And Teverelix Programs On Sept. 29 At Brookline Capital Markets
➖ NeutralBenzinga•Sep 24, 2025, 11:43 AM
Frequently Asked Questions about MDCX
What is MDCX's current stock price?
Medicus Pharma Ltd. Common Stock (MDCX) is currently trading at $1.69 per share. The stock has moved +1.81% today.
What is the analyst price target for MDCX?
No analyst price targets are currently available for this stock.
What sector is Medicus Pharma Ltd. Common Stock in?
Medicus Pharma Ltd. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MDCX's market cap?
Medicus Pharma Ltd. Common Stock has a market capitalization of $0.04 billion, making it a small-cap company.
Does MDCX pay dividends?
No, Medicus Pharma Ltd. Common Stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
BRNS
Barinthus Biotherapeutics plc
$0.74
Mkt Cap: $0.0B
COEP
Coeptis Therapeutics, Inc.
$14.66
Mkt Cap: $0.1B
CUE
Cue Biopharma, Inc.
$0.27
Mkt Cap: $0.0B
CVM
CEL-SCI Corporation
$4.91
Mkt Cap: $0.0B
INMB
INmune Bio, Inc.
$1.83
Mkt Cap: $0.0B
IPSC
Century Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
KPTI
Karyopharm Therapeutics Inc.
$6.94
Mkt Cap: $0.1B
SKYE
Skye Bioscience, Inc.
$0.93
Mkt Cap: $0.0B
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$1.41
Mkt Cap: $0.0B
Explore stocks similar to MDCX for comparison